In Vivo Anticancer Activity, Toxicology and Histopathological Studies of the Thiolate Gold(I) Complex [Au(Spyrimidine)(PTA-CH2Ph)]Br

Anticancer Agents Med Chem. 2015;15(6):773-82. doi: 10.2174/1871520615666150129211440.

Abstract

A physiologically stable thiolate gold(I) derivative [Au(Spyrimidine)(PTA-CH2Ph)]Br has shown inhibition in colon cancer proliferation of Caco-2/TC7, Caco-2/PD7 and HTC-116-luc2 cell lines via apoptotic pathway and S-phase arrest in the cell cycle. Intraperitoneal injection of [Au(Spyrimidine)(PTA-CH2Ph)]Br in athymic nude mice inoculated with HTC-116-luc2 cells prolonged their survival and greatly inhibited tumour growth, near to disappearance. Low concentration of gold in urine and blood were detected in mice after 48 h of administration of 5 mg/kg body weight (bw) of the gold complex and non-organ (kidney and liver) damage has been detected after gold treatment. The results obtained suggested that the thiolate gold(I) derivative shown here could be considered as a candidate for therapeutic treatment in colon cancer.

MeSH terms

  • Animals
  • Antineoplastic Agents / pharmacology*
  • Apoptosis / drug effects
  • Caco-2 Cells
  • Cell Cycle / drug effects
  • Cell Line, Tumor
  • Colonic Neoplasms / drug therapy*
  • Gold / pharmacology*
  • Gold Compounds / pharmacology*
  • HCT116 Cells
  • Humans
  • Mice
  • Mice, Nude
  • Xenograft Model Antitumor Assays

Substances

  • Antineoplastic Agents
  • Gold Compounds
  • Gold